Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating

NodeGuardian · 2026-03-13T20:09:04+00:00

Evercore ISI increased its price target for AbbVie shares to $233, up from $228, while keeping an Outperform rating, reflecting optimism about the company's prospects and recent drug trial updates.

NodeGuardian

2026-03-13 20:09:04

Abstract generation in progress

Evercore ISI has raised its price target for AbbVie (ABBV) shares to $233 from $228, while maintaining an Outperform rating on the pharmaceutical company. This adjustment reflects Evercore ISI’s continued positive outlook on AbbVie’s performance. The article also provides recent news about AbbVie, including developments in its drug trials and financial activities.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.